Introduction
============

Nasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers in Southeast Asia and frequently diagnosed in the southern provinces of China. According to the 2017 National Comprehensive Cancer Network guidelines for the treatment of head and neck cancer, radiotherapy consisting of intensity-modulated radiation therapy (IMRT) and helical tomotherapy or radiotherapy combined with platinum-based chemotherapy remains the standard treatment for NPC. In reality, the majority of patients are initially diagnosed with locoregionally advanced nasopharyngeal carcinoma or even metastatic nasopharyn-geal carcinoma. Radiotherapy[@b1-ott-12-2477]--[@b4-ott-12-2477] is effective against primary lesion and lymph node lesions of NPC due to its obvious short-term effects. However, this treatment modality is associated with poor long-term efficacy and a relatively high occurrence rate of severe adverse reactions. For patients treated with radiotherapy alone, the 5-year survival rate is merely 20%. This low survival is attributed to the high rate of local recurrence and distant metastasis. Compared with radiotherapy, chemotherapy[@b5-ott-12-2477],[@b6-ott-12-2477] is a form of systemic therapy. Currently, the recommended treatment for patients with advanced NPC is concurrent chemoradiotherapy.[@b7-ott-12-2477] However, it lacks optimal bioavailability; its considerable therapeutic benefits are always accompanied by unavoidable increased adverse effects. Hence, a new systemic comprehensive treatment with efficient and tolerable agents is essential.[@b8-ott-12-2477]--[@b11-ott-12-2477]

In recent years, the pursuit of optimal bioavailability contributed to the innovation and exploration of targeted biotherapy. Based on the development of targeted biotherapy and high expression[@b12-ott-12-2477]--[@b16-ott-12-2477] of EGFR, anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR MoAb) including cetuximab (CTX) is considered as a potential addition to the standard concurrent chemoradiotherapy regimen for NPC.[@b17-ott-12-2477] This new systemic comprehensive treatment may improve the anti-tumor efficacy, while maintaining low toxicity. At present, more and more clinical trials[@b18-ott-12-2477]--[@b30-ott-12-2477] have tried the additional treatment of CTX to promote the efficacy of treatment performed as better objective response rate (ORR) and prolonged survival. However, there are no definite comprehensive conclusions regarding the potential benefits of combination treatment with CTX in NPC patients.

Accordingly, we conducted a meta-analysis using pooled data to evaluate the efficacy and safety of the combination treatment with cetuxiamb compared to conventional treatment in NPC patients. In addition, we evaluated the special adverse effects associated with CTX, for example, skin toxicity (ST),[@b31-ott-12-2477],[@b32-ott-12-2477] which manifests as rashes and appears frequently during the treatment of CTX, to explore the relationship between ST and the outcome of combination treatment with cetuxiamb.

Materials and methods
=====================

Literature search
-----------------

We performed systematic electronic searches for relevant articles in PubMed, Embase, Cochrane library, China National Knowledge Infrastructure, and WanFang Data published until December 31, 2017. The following keywords related to skin toxicity ("skin toxicity", "skin rash", "ST"), cetuximab ("cetuximab", "CTX", "anti-EGFR", "targeted therapy"), and nasopharyngeal carcinoma ("nasopharyngeal carcinoma", "nasopharynx cancer", "NPC") were used to retrieve articles and abstracts. Articles published in English and Chinese languages were included, and relevant references from these searched studies were also analyzed. No limitation was used during the literature search. Ethics Committee approval was waived because no human participants or animals were involved in this study.

Study selection and inclusion criteria
--------------------------------------

The studies that met the following inclusion criteria were included in this meta-analysis: 1) prospective or retrospective clinical studies focusing on the treatment of NPC patients with CTX; 2) studies that assessed the outcomes such as efficacy (survival and tumor response) or adverse reactions from additional CTX treatment; 3) studies that described in detail the overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), distant metastasis-free survival (DMFS), complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or adverse reactions in NPC patients with CTX treatment; and 4) studies with more comprehensive analysis so as to avoid duplication of data.

Data extraction
---------------

The collected data from each article were extracted by two authors independently as follows: 1) major characteristics, such as year of publication, first author, country of origin, number of overall patients, clinical stage, therapy strategy, study design; 2) information regarding clinical outcomes, such as CR, PR, SD, PD, OS, PFS, DFS, DMFS, and HR with its corresponding 95% CI that was used as the expression for survival comparison and the unprovided HR (HR were not shown in some articles) and its 95% CI were extracted from Kaplan--Meier curves; and 3) adverse reactions resulting from corresponding treatment, especially ST.

Quality assessment
------------------

The Newcastle--Ottawa Scale (NOS) was used to assess the quality of nonrandomized studies including cohort studies. The highest score for the three aspects of methodological assessment (selection, comparability, and outcome) were 4, 2, and 3, respectively. Studies were considered as high-quality studies if NOS score ≥6. Meanwhile, the risks of bias in randomized controlled trials were assessed by Cochrane Collaboration's tool. According to random sequence generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome data, selective reporting, and other biases, the risk was evaluated as high, low, or unclear. Two investigators evaluated the included studies independently and sequent disagreements were resolved by discussion with a third investigator. Eventually, a total of 23 studies[@b34-ott-12-2477]--[@b56-ott-12-2477] were included in the analysis.

Statistical analysis
--------------------

Referring to PRISMA guideline (PRISMA 2009 checklist),[@b33-ott-12-2477] OS, PFS, DFS, and DMFS expressed as HR and corresponding 95% CI were considered to be the primary endpoints, and ORR expressed as risk ratio (RR) and corresponding 95% CI were the secondary endpoints. Meanwhile, the risk of occurrence of adverse reactions (ST) was expressed as risk ratio (RR) and its 95% CI as well. Pooled data were calculated with Revman 5.3 software (Cochrane Center) and Stata 14.0 (Stata Corp., College Station, TX, USA). The effect model was chosen according to heterogeneity. If the heterogeneity was not significant (*P*\>0.1, *I*^2^\<50.0%), then a fixed-effect model was performed, whereas if the heterogeneity was significant, then a random-effect model was used. The results of meta-analysis were presented as forest plots and *P*-value \<0.05 was considered significant. Sensitivity analysis was performed by sequentially excluding individual studies to evaluate the stability of results. Publication bias was presented as funnel plots and detected by Begg's test and Egger's test.

Results
=======

Description of studies
----------------------

After excluding 401 irrelevant studies, 105 studies were chosen, from which 36 duplicate studies were excluded subsequently ([Figure 1](#f1-ott-12-2477){ref-type="fig"}). Finally, 23 studies[@b34-ott-12-2477]--[@b56-ott-12-2477] presenting the clinical outcome of additional CTX treatment were included in the analysis.

The general characteristics of the included studies with a total of 3,177 patients are summarized in [Table 1](#t1-ott-12-2477){ref-type="table"}. The studies were published from 2013 to 2017, and the number of samples ranged from 22 to 791. All included studies were from China, which were consistent with the finding of the WHO that 80% of NPCs occur in China.[@b57-ott-12-2477] Of the 23 studies conducted, 16 studies focused on the effect of CTX combined with concurrent chemoradiotherapy, five studies on IMRT only, and two studies on chemotherapy only. Moreover, a majority of patients were treated with platinum-based chemotherapy, containing cisplatin, nedaplatin, carboplatin, and lobaplatin. A total of 17 studies[@b37-ott-12-2477],[@b39-ott-12-2477]--[@b42-ott-12-2477],[@b44-ott-12-2477]--[@b48-ott-12-2477],[@b50-ott-12-2477]--[@b56-ott-12-2477] and nine studies[@b34-ott-12-2477],[@b35-ott-12-2477],[@b38-ott-12-2477],[@b41-ott-12-2477],[@b43-ott-12-2477],[@b49-ott-12-2477] assessed the outcomes of response rates and survival rates, respectively. Twenty-one studies[@b34-ott-12-2477]--[@b44-ott-12-2477],[@b46-ott-12-2477]--[@b55-ott-12-2477] described a series of adverse reactions due to the treatment and 11[@b34-ott-12-2477],[@b37-ott-12-2477],[@b38-ott-12-2477],[@b40-ott-12-2477],[@b44-ott-12-2477],[@b46-ott-12-2477],[@b48-ott-12-2477]-- [@b50-ott-12-2477],52,54 of these studies assessed the ST associated with CTX.

Quality of assessment
---------------------

Risk of bias was used to assess the quality of 13 randomized trials.[@b36-ott-12-2477],[@b37-ott-12-2477],[@b40-ott-12-2477],[@b42-ott-12-2477],[@b44-ott-12-2477],[@b46-ott-12-2477]--[@b48-ott-12-2477],[@b51-ott-12-2477]--[@b54-ott-12-2477],[@b56-ott-12-2477] Of those, four studies had low risk of bias and nine had unclear risk ([Figures S1](#SD1-ott-12-2477){ref-type="supplementary-material"} and [S2](#SD1-ott-12-2477){ref-type="supplementary-material"}). The bias mostly resulted from allocation concealment, blinding of participants and personnel, and outcome assessment. In addition, the NOS scores of ten nonrandomized studies[@b34-ott-12-2477],[@b35-ott-12-2477],[@b38-ott-12-2477],[@b39-ott-12-2477],[@b41-ott-12-2477],[@b43-ott-12-2477],[@b45-ott-12-2477],[@b49-ott-12-2477],[@b50-ott-12-2477],[@b55-ott-12-2477] were all ≥6 ([Table 2](#t2-ott-12-2477){ref-type="table"}), thereby indicating that the overall quality of the cohort studies was high.

Survival: comparison between combination treatment with CTX and conventional treatment ([Figure 2A and B](#f2-ott-12-2477){ref-type="fig"})
-------------------------------------------------------------------------------------------------------------------------------------------

In studies with CTX treatment, available data on OS,[@b34-ott-12-2477],[@b35-ott-12-2477],[@b38-ott-12-2477],[@b39-ott-12-2477],[@b41-ott-12-2477]-- [@b43-ott-12-2477],49,53 PFS,[@b34-ott-12-2477],[@b39-ott-12-2477],[@b43-ott-12-2477] DMFS,[@b35-ott-12-2477],[@b36-ott-12-2477],[@b38-ott-12-2477],[@b43-ott-12-2477],[@b49-ott-12-2477] and DFS[@b35-ott-12-2477],[@b36-ott-12-2477],[@b38-ott-12-2477],[@b49-ott-12-2477] were provided. By comparing experimental group with control group ([Figure 2A](#f2-ott-12-2477){ref-type="fig"}), the pooled HR for OS was 0.70 (95% CI: 0.55--0.89, *P*=0.003), and no publication bias was detected using Begg's test (*P*=0.835) and Egger's test (*P*=0.817) ([Figure S3](#SD1-ott-12-2477){ref-type="supplementary-material"}). The pooled HR for PFS was 0.63 (95% CI: 0.39--1.02, *P*=0.06), for DMFS was 0.57 (95% CI: 0.41--0.81, *P*=0.001), and for DFS was 0.70 (95% CI: 0.52--0.94, *P*=0.02). Moreover, to stress the efficacy of additional CTX and avoid the difference in treatments, studies that focused on concurrent chemo-radiotherapy (2D-CRT or IMRT combined with cisplatin) with or without CTX were selected. As a result ([Figure 2B](#f2-ott-12-2477){ref-type="fig"}), the pooled HR for OS was 0.64 (95% CI: 0.49--0.84, *P*=0.001), for PFS was 0.56 (95% CI: 0.33--0.96, *P*=0.04), for DMFS was 0.48 (95% CI: 0.32--0.73, *P*=0.0007), and for DFS was 0.62 (95% CI: 0.42--0.91, *P*=0.02). Analysis of the comprehensive outcome of survival suggested that patients treated with CTX could benefit from the combination CTX treatment with longer OS, decreased risk of metastasis, and relapse.

Response rate: comparison between combination treatment with CTX and conventional treatment ([Figure 3A and B](#f3-ott-12-2477){ref-type="fig"})
------------------------------------------------------------------------------------------------------------------------------------------------

Data on ORR, including CR and PR, were extracted from 17 studies[@b37-ott-12-2477],[@b39-ott-12-2477]--[@b42-ott-12-2477],[@b44-ott-12-2477]--[@b48-ott-12-2477],[@b50-ott-12-2477]--[@b56-ott-12-2477] involving a total of 1,242 NPC patients. In patients who underwent several treatment options with CTX (concurrent chemoradiotherapy with or without CTX, IMRT with or without CTX, and chemotherapy with or without CTX), the experimental group showed a significantly improved response rate (RR: 1.39, 95% CI: 1.29--1.50, *P*\<0.00001) when compared with the control group ([Figure 3A](#f3-ott-12-2477){ref-type="fig"}). To eliminate the synergistic efficiency obtained from chemotherapy and avoid differences in treatments, different treatment options with CTX were analyzed to further evaluate the efficacy of the additional CTX treatment. The results ([Figure 3B](#f3-ott-12-2477){ref-type="fig"}) showed that the addition of CTX to concurrent chemoradiotherapy (RR: 1.39, 95% CI: 1.25--1.54, *P*\<0.00001), IMRT (RR: 1.45, 95% CI: 1.24--1.69, *P*\<0.00001), and chemotherapy (RR: 2.48, 95% CI: 1.00--6.17, *P*=0.05) all achieved a better response rate. No significant publication bias ([Figure S4](#SD1-ott-12-2477){ref-type="supplementary-material"}) was observed in Begg's test (*P*=0.127) and Egger's test (*P*=0.251).

Adverse reactions (except ST): comparison between combination treatment with CTX and conventional treatment ([Figure 4A and B](#f4-ott-12-2477){ref-type="fig"})
----------------------------------------------------------------------------------------------------------------------------------------------------------------

A total of 21 studies,[@b34-ott-12-2477]--[@b44-ott-12-2477],[@b46-ott-12-2477]--[@b55-ott-12-2477] including the studies on CTX treatment, provided data on a series of adverse reactions, including hematologic reactions (leukopenia, thrombocytopenia, anemia, hepatotoxicity, and neph-rotoxicity) and non-hematologic reactions (mucositis, vomiting, nausea, diarrhea, weight loss, and radiothermitis). The pooled results showed ([Figure 4A](#f4-ott-12-2477){ref-type="fig"}) that there were no notable differences in the rate of occurrence of thrombocytopenia (RR: 0.98, 95% CI: 0.5--1.94, *P*=0.96), anemia (RR: 0.72, 95% CI: 0.29--1.78, *P*=0.48), hepatotoxicity (RR: 1.13, 95% CI: 0.63--2.04, *P*=0.68), nephrotoxicity (RR: 0.66, 95% CI: 0.24--1.80, *P*=0.41), vomiting (RR: 0.83, 95% CI: 0.57--1.20, *P*=0.31), nausea (RR: 0.81, 95% CI: 0.63--1.04, *P*=0.10), weight loss (RR: 1.01, 95% CI: 0.66--1.54, *P*=0.98), and radiothermitis (RR: 0.84, 95% CI: 0.58--1.21, *P*=0.36) between the experimental and control groups. However, the rate of occurrence of leukopenia in the experimental group was significantly lower compared to that in the control group (RR: 0.81, 95% CI: 0.69--0.96, *P*=0.01), and the rates of occurrence of mucositis and diarrhea in the experimental group were higher compared to that in the control group (RR: 1.33, 95% CI: 1.12--1.58, *P*=0.001; RR: 1.56, 95% CI: 1.30--1.87, *P*\<0.00001). In addition, studies that focused on the treatment of concurrent chemoradiotherapy with or without CTX ([Figure 4B](#f4-ott-12-2477){ref-type="fig"}) showed that the combination of CTX and chemoradiotherapy did not increase the rate of occurrence of leukopenia (RR: 0.98, 95% CI: 0.84--1.14, *P*=0.80), thrombocytopenia (RR: 0.69, 95% CI: 0.44--1.08, *P*=0.10), anemia (RR: 0.55, 95% CI: 0.19--1.60, *P*=0.27), nephrotoxicity (RR: 0.91, 95% CI: 0.51--1.65, *P*=0.76), mucositis (RR: 1.16, 95% CI: 0.98--1.38, *P*=0.08), vomiting (RR: 1.20, 95% CI: 0.91--1.60, *P*=0.20), nausea (RR: 0.90, 95% CI: 0.78--1.04, *P*=0.15), and radiothermitis (RR: 0.84, 95% CI: 0.58--1.21, *P*=0.36) when compared with studies on chemoradiotherapy alone. Besides, higher rates of occurrence of hepatotoxicity, diarrhea, and weight loss were observed in group that underwent combination treatment with CTX (RR: 1.77, 95% CI: 1.06--2.95, *P*=0.03; RR: 1.52, 95% CI: 1.26--1.85, *P*\<0.0001; RR: 1.13, 95% CI: 1.01--1.27, *P*=0.04).

ST: comparison between combination treatment with CTX and conventional treatment ([Figure 5A and B](#f5-ott-12-2477){ref-type="fig"})
-------------------------------------------------------------------------------------------------------------------------------------

We collected data regarding ST, which presented as rashes, from 11 studies that focused on CTX treatment,[@b34-ott-12-2477],[@b37-ott-12-2477],[@b38-ott-12-2477],[@b40-ott-12-2477], [@b44-ott-12-2477],46,48--50,52,54 and a higher occurrence rate of ST was observed in the experimental group (RR: 2.46, 95% CI: 1.81--3.34, *P*,0.00001) ([Figure 5A](#f5-ott-12-2477){ref-type="fig"}). Moreover, studies on patients who underwent treatment with concurrent chemoradio-therapy with or without CTX also showed that addition of CTX increased the occurrence rate of ST compared to the studies on those who underwent treatment with concurrent chemoradiotherapy (RR: 1.84, 95% CI: 1.02--3.31, *P*=0.04) ([Figure 5B](#f5-ott-12-2477){ref-type="fig"}). Based on these pooled data, it can be concluded that ST is more likely to occur in patients who undergo combined treatment with CTX. In other words, patients treated with CTX could obtain more benefit from additional treatment, but with more occurrences of ST. The publication bias was analyzed by Begg's test (*P*=0.755) and Egger's test (*P*=0.512) and is shown in funnel plots ([Figure S5](#SD1-ott-12-2477){ref-type="supplementary-material"}).

Discussion
==========

Following the widespread use of anti-EGFR MoAb, CTX and nimotuzumab are the preferred treatment of choice for NPC. Due to the high occurrence of NPC in China, several studies have tried to examine the efficacy of CTX combined with nimotuzumab, and comprehensive statistics articles have already evaluated the efficacy of nimotuzumab combined with chemoradiotherapy.[@b58-ott-12-2477] Our study is the first to make a definite comprehensive conclusion with regard to the potential benefits of combination treatment with CTX in NPC patients.

This systematic literature retrieval and meta-analysis of the relevant articles aimed to assess the therapeutic effect of combination treatment with CTX compared to the conventional treatment for NPC. The comprehensive analysis suggested that patients who accepted additional CTX treatment could obtain more benefits, such as increased response rate and prolonged survival, from combina tion treatment. Besides, the two treatment methods did not show any significant difference in the rates of occurrence of most adverse reactions. It seemed that the treatment plan of CTX is more feasible and efficient for NPC with similar adverse reactions when compared with conventional treatment.

With regard to clinical outcome of efficacy (survival and response rate), the pooled HR for OS, DMFS, and DFS in survival and the pooled RR for ORR are significant for CTX treatment compared with conventional treatment (*P*,0.05). When studies with treatment of concurrent chemoradiotherapy with or without CTX were selected, the superiority of combination CTX treatment compared to chemoradiotherapy for NPC patients was found for OS, PFS, DMFS, and DFS in survival and ORR (*P*\<0.05). Nevertheless, the studies included were still insufficient, especially the studies that reported data about PFS, DMFS, and DFS (n≤5). Further, the indicator of survival would be more accurate with increasing relevant research.

With regard to adverse reactions, addition of CTX did not increase the risk of occurrence of adverse reactions, thereby indicating the safety of additional CTX treatment. We emphasized the assessment of ST in our study, which seemed to be a potential on-treatment marker for anti-EGFR MoAb treatment.[@b59-ott-12-2477] Currently, anti-EGFR MoAb is widely used in the clinical treatment and has provided new treatment options for a variety of malignant tumors. CTX served as a kind of anti-EGFR MoAb when used in the treatment of colorectal cancer, lung cancer, and NPC. Compared with conventional therapy for NPC, which barely showed any significant effi-cacy, CTX has provided a new direction in the treatment of NPC. In clinical application, the selection of an anti-EGFR MoAb is normally directed by molecular markers (EGFR, K-ras, and so on) before targeted treatment. However, the molecular markers do not ensure an absolutely effective anti-EGFR treatment due to the complexity and variability that arise during the treatment. Therefore, the observation of an on-treatment clinical marker is of equal importance. ST is considered to be an adverse effect that arises due to EGFR inhibition, and it seems to be a potential predictor of better response to personalized anti-EGFR treatment. In one of the studies included in this meta-analysis,[@b34-ott-12-2477] the results of univariate analysis showed that CTX-treated patients with grade 3--4 rashes presented with better OS outcomes compared to those with grade 0--2 rashes. Therefore, ST has been concluded to be a potential predictor, and based on this on-treatment marker, suitable clinical decision about anti-EGFR strategies during the treatment of CTX could be made. Future work should focus on whether ST could predict the absolute benefit of the addition of CTX in the treatment of NPC. Besides, future studies should also focus on how to use this on-treatment marker in clinical decision-making and determine the predict value of ST in additional CTX treatment of NPC.

Furthermore, this study has some limitations in spite of the confirmation of our statistical results with the sensitivity analysis. Firstly, the included studies were of diverse quality with different clinical settings and standard treatment plans. Although the studies investigating CCRT with or without cetuximab were selected to pool the corresponding data, this may have led to significant heterogeneity and influenced the interpretation of the results. Secondly, some subanalyses involved only a small number of studies, so the analysis results from these studies were unstable. With more relevant studies in the future, the accuracy of the results would increase. Thirdly, only articles in English and Chinese were included, and all the available information were from China, which led to potential publication bias.

Conclusion
==========

The anti-EGFR MoAb, CTX, showed improved efficacy in combination treatment compared with conventional treatment. In other words, NPC patients could obtain definite benefits from additional treatment with CTX. Moreover, ST, a significant adverse effect associated with CTX treatment, may serve as an on-treatment marker to guide treatment with CTX against NPC.

Supplementary materials
=======================

Item 8 -- Presents full electronic search strategy for at least one database, including any limits used, such that it could be repeated.

For example, search strategy for PubMed, keywords related to skin toxicity ("skin toxicity", "skin rash"), cetuximab ("cetuximab", "CTX", "anti-EGFR", "targeted therapy"), and nasopharyngeal carcinoma ("nasopharyngeal carcinoma", "nasopharynx cancer", "NPC") were used to retrieve articles and abstracts in PubMed. The search builder was ((cetuximab \[Mesh Terms\]) OR (cetuximab \[Title/ Abstract\]) OR (CTX \[Title/Abstract\]) OR (anti-EGFR \[Title/ Abstract\]) OR (targeted therapy \[Title/Abstract\])) AND ((nasopharyngeal carcinoma \[Mesh Terms\]) OR (nasopha-ryngeal carcinoma \[Title/Abstract\]) OR (nasopharynx cancer \[Title/Abstract\]) OR (NPC \[Title/Abstract\])) AND ((skin toxicity \[Mesh Terms\]) OR (skin toxicity \[Title/Abstract\]) OR (skin rash \[Title/Abstract\])). No limitation was used during the literature search.

###### 

Risk of bias and summary of applicability concerns: review authors' judgments about each domain for each included study.

**Note:** No studies had a high risk of bias.

###### 

Risk of bias and graph of applicability concerns: review authors' judgments about each domain presented as percentages across included studies.

###### 

Funnel plot with pseudo 95% CI of publication bias.

###### 

Funnel plot with pseudo 95% CI of publication bias.

###### 

Funnel plot with pseudo 95% CI of publication bias.
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###### 

(**A**) Forest plot of combination treatment with cetuximab versus conventional treatment on outcome of survival (OS, PFS, DMFS, and DFS). (**B**) Forest plot of treatment of concurrent chemoradiotherapy with or without cetuximab on outcome of survival (OS, PFS, DMFS, and DFS).

**Abbreviations:** OS, overall survival; PFS, progression-free survival; DMFS, distant metastasis-free survival; DFS, disease-free survival.
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![(**A**) Forest plot of combination treatment with CTX versus conventional treatment on the outcome of response rate (ORR). (**B**) Forest plot of treatment of concurrent chemoradiotherapy with or without cetuximab, IMRT with or without cetuximab, chemotherapy with or without cetuximab on ORR.\
**Abbreviations:** CCRT, concurrent chemoradiotherapy; Chem, chemotherapy; CTX, cetuximab; IMRT, intensity-modulated radiotherapy.](ott-12-2477Fig3){#f3-ott-12-2477}

###### 

(**A**) Forest plot of combination treatment with cetuximab versus conventional treatment on outcome of adverse reactions (except skin toxicity). (**B**) Forest plot of treatment of concurrent chemoradiotherapy with or without cetuximab on outcome of adverse reactions (except skin toxicity).
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![(**A**) Forest plot of combination treatment with cetuximab versus conventional treatment on outcome of skin toxicity (ST). (**B**) Forest plot of treatment of concurrent chemoradiotherapy with or without cetuximab on outcome of ST.](ott-12-2477Fig5){#f5-ott-12-2477}

###### 

Characteristics of included studies

  Authors                         Year   City and country   Number of samples (E/C)   Stage     Treatment                   CTX                                                           Chemotherapy                                                          Radiotherapy                                                   Outcome          ST                     
  ------------------------------- ------ ------------------ ------------------------- --------- --------------------------- ------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------- ---------------- ---------------------- -----------------------------------
  Wu et al[@b34-ott-12-2477]      2016   Chengdu, China     112 (56/56)               II--IV    IMRT + CTX vs IMRT + CDDP   400 mg/m^2^ loading dose and then 250 mg/m^2^/w 8 cycles      CDDP (25 mg/m^2^, d~1~--d~3~/3w) 3 cycles                             IMRT/a total of 70 to 74 Gy                                    --               OS, PFS                IMRT + CTX:21/ IMRT + CDDP:2
  Xia et al[@b35-ott-12-2477]     2017   Guangzhou, China   192 (96/96)               --        CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w               CDDP (30--40 mg/m^2^/w, 80--100 mg/m^2^/3w)                           2D-CRT or IMRT                                                 --               OS, DFS, DMFS, LRRFS   --
  Xu et al[@b36-ott-12-2477]      2015   Shanghai, China    44 (21/23)                III--IV   IMRT + CTX vs IMRT + CDDP   400 mg/m^2^ loading dose and then 250 mg/m^2^/w               CDDP (30--40 mg/m^2^/w)                                               IMRT/a total of 66 to 70.4 Gy                                  CR, PR           OS, DFS, MFS, RFS      --
  Zhou et al[@b37-ott-12-2477]    2017   Luohe, China       120 (60/60)               III--IV   IMRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w 4 cycles      N                                                                     IMRT/a total of 70 Gy                                          CR, PR, SD, PD   --                     IMRT + CTX:6/ IMRT:2
  You et al[@b38-ott-12-2477]     2017   Guangzhou, China   791 (102/689)             II--IV    CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w               CDDP (100 mg/m^2^/3w) 3 cycles                                        IMRT/a total of 66 to 70 Gy                                    --               OS, DFS, MFS, RFS      CCRT + CTX:82/ CCRT:224
  Wang et al[@b39-ott-12-2477]    2016   Yulin, China       78 (36/42)                I--IV     CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w 6 cycles      CDDP (40 mg/m^2^/w) 6 cycles                                          IMRT/a total of 66 Gy                                          CR, PR, SD, PD   OS, PFS                --
  Sun et al[@b40-ott-12-2477]     2016   Jinzhou, China     100 (50/50)               III--IV   IMRT ± CDDP + CTX           400 mg/m^2^ loading dose and then 250 mg/m^2^/w 7 cycles      CDDP (20 mg/m^2^/4w) 4 cycles                                         IMRT/a total of 70 Gy                                          CR, PR, SD, PD   --                     IMRT + CDDP + CTX:24/IMRT:6
  Zeng et al[@b41-ott-12-2477]    2016   Chongqin, China    138 (64/74)               III--IV   CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w 6 cycles      CDDP (40 mg/m^2^/w) 6 cycles                                          IMRT/a total of 64 to 86 Gy                                    CR, PR, SD, PD   OS, DMFS, LRFS         --
  Cao et al[@b42-ott-12-2477]     2016   Enshi, China       40 (20/20)                III--IV   CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w 8 cycles      CDDP (33 mg/m^2^, d~1~--d~3~/3w)                                      IMRT/a total of 69 Gy                                          CR, PR, SD, PD   SR                     --
  Li et al[@b43-ott-12-2477]      2017   Guangzhou, China   186 (62/124)              II--IV    CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w 6--7 cycles   CDDP (80--100 mg/m^2^/w) 2 cycles or (30--40 mg/m^2^/w) 5--7 cycles   2D-CRT/a total of 70 to 76 Gy or IMRT/a total of 68 to 72 Gy   --               OS, DFS, DMFS, LRFS    --
  Yang et al[@b44-ott-12-2477]    2016   Huanggang, China   45 (22/23)                III--IV   CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w 7 cycles      CDDP (40 mg/m^2^/w) 6--8 cycles                                       IMRT/a total of 73.96 Gy                                       CR, PR, SD, PD   --                     IMRT + CDDP + CTX:19/IMRT:18
  Fu et al[@b45-ott-12-2477]      2015   Yichun, China      64 (36/28)                --        CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg mg/m^2^/w            CDDP (20 mg/m^2^/4w) 4 cycles                                         IMRT/a total of 70 Gy                                          CR, PR, SD, PD   OS, DMFS, LRFS         --
  Zhao et al[@b46-ott-12-2477]    2015   Fuzhou, China      64 (32/32)                III--IV   CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w               CDDP (20 mg/m^2^/3w) 4 cycles                                         IMRT/a total of 64 to 72 Gy                                    CR, PR, SD, PD   --                     IMRT + CDDP + CTX:7/IMRT:5
  Yao et al[@b47-ott-12-2477]     2015   Wuhan, China       37 (19/18)                IV        Chem ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w \$2 cycles    GEM (1,250 mg/m^2^, d~1~,d~8~)+NDP (80 mg/m^2^, d~1~)                 N                                                              ORR, DCR         mOS, mPFS              --
  Wang et al[@b48-ott-12-2477]    2015   Dongguan, China    30 (15/15)                III--IV   IMRT ± CDDP + GEM + CTX     300 mg/m^2^ loading dose and then 200 mg/m^2^/w 10 cycles     GEM (0.5 mg/m^2^, d~1~,d~6~/2w) + CDDP (20 mg/m^2^, d~1~--d~5~/2w)    IMRT/a total of 56 to 70 Gy                                    CR, PR, SD, PD   --                     IMRT + CDDP + GEM + CTX:5/ IMRT:2
  You et al[@b49-ott-12-2477]     2017   Guangzhou, China   630 (58/572)              II--IV    IMRT + CTX vs IMRT + CDDP   --                                                            --                                                                    IMRT/a total of 66 to 70 Gy                                    --               OS, DFS, DMFS, LRRFS   IMRT + CTX:44/ IMRT + CDDP:181
  Zhou et al[@b50-ott-12-2477]    2013   Xuchang, China     126 (63/63)               --        IMRT ± CDDP + CTX           400 mg/m^2^ loading dose and then 250 mg/m^2^/w               CDDP (20 mg/m^2^/4w) 4 cycles                                         IMRT/a total of 70 Gy                                          CR, PR, SD, PD   --                     IMRT + CDDP + CTX:24/IMRT:9
  Zheng et al[@b51-ott-12-2477]   2013   Foshan, China      40 (20/20)                --        CCRT ± CTX                  300 mg/m^2^ loading dose and then 200 mg/m^2^/w 7 cycles      CDDP (80 mg/m^2^/3w) 2 cycles                                         IMRT/a total of 69.96 Gy                                       ORR              --                     --
  Tang et al[@b52-ott-12-2477]    2013   Bijie, China       110 (55/55)               III--IV   IMRT ± CDDP + CTX           400 mg/m^2^ loading dose and then 250 mg/m^2^/w               CDDP (20 mg/m^2^/4w) 4 cycles                                         IMRT/a total of 70 to 74 Gy                                    CR, PR, SD, PD   --                     IMRT + CDDP + CTX:26/IMRT:7
  Fu et al[@b53-ott-12-2477]      2015   Haikou, China      40 (20/20)                --        CCRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w 6 cycles      CDDP (33 mg/m^2^, d~1~--d~3~/3w)                                      IMRT/a total of 69 Gy                                          CR, PR, SD, PD   SR                     --
  Wu et al[@b54-ott-12-2477]      2013   Chengdu, China     68 (34/34)                III--IV   CCRT ± CTX                  100 mg/w 7 cycles                                             CDDP (20 mg/m^2^, d~1~--d~4~/3w) 2 cycles                             IMRT/a total of 64 to 68 Gy                                    CR, PR, SD, PD   --                     CCRT + CTX:16/ CCRT:5
  Gao et al[@b55-ott-12-2477]     2013   Guangzhou, China   22 (10/12)                --        Chem ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w               GEM (1,250 mg/m [@b2-ott-12-2477],                                    N                                                              ORR              mOS, mPFS              --
  Peng et al[@b56-ott-12-2477]    2013   Shandong, China    100 (50/50)               --        IMRT ± CTX                  400 mg/m^2^ loading dose and then 250 mg/m^2^/w               N                                                                     IMRT/a total of 70 Gy                                          CR, PR, SD, PD   LCR, SR                --

**Abbreviations:** CTX, cetuximab; CDDP, cisplatin; GEM, gemcitabine; NDP, nedaplatin; CBP, carboplatin; IMRT, intensity-modulated radiotherapy; 2D-CRT, two-dimensional conventional radiotherapy; CCRT, concurrent chemoradiotherapy; Chem, chemotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR (CR + PR), objective response rate; DCR (CR + PR + SD), disease control rate; OS, overall survival; PFS, progression-free survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; MFS, metastasis-free survival; RFS, relapse-free survival; LRFS, local relapse-free survival; LRRFS, locoregional relapse-free survival; SR, survival rate; LCR, local control rate; E, experimental team; C, control team; N, none (patients did not receive the corresponding treatment).

###### 

Methodological quality assessment of included studies by Newcastle--Ottawa Scale

  Study                          Selection                                      Comparability                                  Outcome                                        Total                                                                                                                                                                                                                                        
  ------------------------------ ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ------------------------------------------------ ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---
  Wu et al[@b34-ott-12-2477]     [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}     [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   8
  Xia et al[@b35-ott-12-2477]    [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*\*](#tfn3-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   9
  You et al[@b38-ott-12-2477]    [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*\*](#tfn3-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   --                                             8
  Li et al[@b43-ott-12-2477]     [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*\*](#tfn3-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   9
  You et al[@b49-ott-12-2477]    [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}     [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   --                                             7
  Wang et al[@b39-ott-12-2477]   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*\*](#tfn3-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   --                                             8
  Zeng et al[@b41-ott-12-2477]   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*\*](#tfn3-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   --                                             8
  Fu et al[@b45-ott-12-2477]     [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*\*](#tfn3-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   --                                             8
  Zhou et al[@b50-ott-12-2477]   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}     [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   --                                             --                                             6
  Gao et al[@b55-ott-12-2477]    [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*\*](#tfn3-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   [\*](#tfn2-ott-12-2477){ref-type="table-fn"}   --                                             8

**Notes:**

One point;

two points.

[^1]: These authors contributed equally to this work
